Lupin gets USFDA approval for diabetes management drug

Lupin today said it has received final approval from the US health regulator to sell generic diabetes management drug Pioglitazone Tablets in the American market.

Lupin said its US subsidiary, Lupin Pharmaceuticals Inc has received final approval for its Pioglitazone tablets from the US Food and Drugs Administration to market generic version of Takeda Pharmaceuticals USA Inc's Actos tablets.

The company said in a BSE filing that its subsidiary will shortly commence marketing the product.

The approval has been granted for tablets in strengths of 15 mg, 30 mg and 45mg.

"Lupin's Pioglitazone tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings," the company said.

As per IMS MAT December data, Actos tablets had annual US sales of USD 236 million.


  • India’s economic recovery has to be consumption, and not investment, led

    It is well accepted that falling global commodity prices, especially oil, have helped the Indian economy regain lustre in the past year or so.


Stay informed on our latest news!


Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs


Amita Sharma

Smart cities for the smart citizens

The 21st century has been spoken of as the urban ...

Purnendu Ghosh

Too shy people love themselves too much

We are essentially shy people. Our extent of shyness, however, ...

Shona Adhikari

When nature and naturism have a date

DAG Modern has announced its forthcoming exhibition The Naked and ...


William D. Green

Chairman & CEO, Accenture